Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 20Genitourinary 14Thoracic 10Tumor-Agnostic 2Other solid neoplasm 2Gynecologic 2CNS 2Head & Neck 1

Conditions

Neoplasm Metastasis 2

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Standard of Care 10Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Capecitabine 7Surveys and Questionnaires 6Gemcitabine 6Cyclophosphamide 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Radiotherapy 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
sacituzumab govitecan × Tumor-Agnostic × 90 days × Clear all
NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03964727 2026-04-28

TROPiCS-03

Gilead Sciences

Phase 2 Active not recruiting
227 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡